Synairgen Plc - Company Profile
Powered by 
All the data and insights you need on Synairgen Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Synairgen Plc Strategy Report
- Understand Synairgen Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma, COVID-19 and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) in Phase II clinical trials for chronic obstructive pulmonary disease (COPD) and COVID-19. The company in partnership with Pharmaxis investigating, lysyl oxidase-like protein 2 (LOXL2), a small molecule inhibitor in Phase I clinical trials for the treatment of fibrotic disease. Synairgen develops drugs and tissue models based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells, and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.
Headquarters
United Kingdom
Address
Southampton General Hosp, Tremona Road, England, SO166YD
Website
www.synairgen.com
Telephone
44 23 80512800
No of Employees
30
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SNG (LON)
EPS
XYZ
Net Income (2022)
XYZ
63.7%
(2022 vs 2021)
Market Cap*
$16.8M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Synairgen Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| IFN-beta: |
| COVID-19 |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Synairgen Plc | Novartis AG | GSK plc | ALK-Abello AS | Napp Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | Switzerland | United Kingdom | Denmark | United Kingdom |
| City | Southampton | Basel | Brentford | Hoersholm | Cambridge |
| State/Province | England | - | England | - | England |
| No. of Employees | 30 | 103,000 | 69,400 | 2,727 | 194 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Marsden | Chief Executive Officer; Director | Executive Board | 2009 | - |
| Joseph Colliver | Chief Financial Officer; Director | Executive Board | 2023 | - |
| Phillip Monk | Chief Scientific Officer; Director | Executive Board | 2009 | - |
| Marcin Mankowski | Chief Medical Officer | Senior Management | 2023 | - |
| Richard Hennings | Chief Commercial Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward